Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Tiede

Showing results (41-50 of 121) with videos related to

Pageof 13
Sort By:
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 25, 2021
Post-hoc analysis on the long-term response to fixed-dose prophylaxis with N8-GP in patients with haemophilia AAndreas Tiede, Kingsley Hampton, Victor Jiménez-Yuste, et al.
Viruses|August 26, 2022
Long-Term Outcomes after Vaccine-Induced Thrombotic ThrombocytopeniaVictoria Panagiota, Christiane Dobbelstein, Sonja Werwitzke, et al.
Thrombosis and Haemostasis|February 3, 2026
Pharmacodynamic interaction between emicizumab and coagulation Factor VIIIMatthias Chill, Emma Louise Konarski, Annika Klingberg, et al.
Journal of Blood Medicine|November 10, 2021
Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia AParth Vashi, Katharine Batt, Robert Klamroth, et al.
Acta Haematologica|January 27, 2022
Distinct Mechanisms of IgM Antibody-Mediated Acquired von Willebrand Syndrome and Successful Treatment with Recombinant von Willebrand Factor in One PatientMatthias Höpting, Ulrich Budde, Andreas Tiede, et al.
Blood|August 4, 2012
Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patientsElena Santagostino, Claude Negrier, Robert Klamroth, et al.
Seminars in Thrombosis and Hemostasis|September 14, 2013
Pathogen safety of long-term treatments for bleeding disorders: (un)predictable risks and evolving threatsGiovanni Di Minno, Mariana Canaro, James W Ironside, et al.
Haematologica|October 5, 2013
Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practiceGiovanni Di Minno, Mariana Canaro, James W Ironside, et al.
Thrombosis and Haemostasis|August 7, 2015
Deletion or inhibition of Fc gamma receptor 2B (CD32) prevents FVIII-specific activation of memory B cells in vitroSonja Werwitzke, Nadine Vollack, Marcus von Hornung, et al.
Blood Reviews|September 19, 2015
Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disordersGiovanni Di Minno, Carlo Federico Perno, Andreas Tiede, et al.
Pageof 13

Showing results (41-50 of 121) with videos related to

Sort By:
Pageof 13
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 25, 2021
Post-hoc analysis on the long-term response to fixed-dose prophylaxis with N8-GP in patients with haemophilia AAndreas Tiede, Kingsley Hampton, Victor Jiménez-Yuste, et al.
Viruses|August 26, 2022
Long-Term Outcomes after Vaccine-Induced Thrombotic ThrombocytopeniaVictoria Panagiota, Christiane Dobbelstein, Sonja Werwitzke, et al.
Thrombosis and Haemostasis|February 3, 2026
Pharmacodynamic interaction between emicizumab and coagulation Factor VIIIMatthias Chill, Emma Louise Konarski, Annika Klingberg, et al.
Journal of Blood Medicine|November 10, 2021
Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia AParth Vashi, Katharine Batt, Robert Klamroth, et al.
Acta Haematologica|January 27, 2022
Distinct Mechanisms of IgM Antibody-Mediated Acquired von Willebrand Syndrome and Successful Treatment with Recombinant von Willebrand Factor in One PatientMatthias Höpting, Ulrich Budde, Andreas Tiede, et al.
Blood|August 4, 2012
Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patientsElena Santagostino, Claude Negrier, Robert Klamroth, et al.
Seminars in Thrombosis and Hemostasis|September 14, 2013
Pathogen safety of long-term treatments for bleeding disorders: (un)predictable risks and evolving threatsGiovanni Di Minno, Mariana Canaro, James W Ironside, et al.
Haematologica|October 5, 2013
Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practiceGiovanni Di Minno, Mariana Canaro, James W Ironside, et al.
Thrombosis and Haemostasis|August 7, 2015
Deletion or inhibition of Fc gamma receptor 2B (CD32) prevents FVIII-specific activation of memory B cells in vitroSonja Werwitzke, Nadine Vollack, Marcus von Hornung, et al.
Blood Reviews|September 19, 2015
Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disordersGiovanni Di Minno, Carlo Federico Perno, Andreas Tiede, et al.
Pageof 13